Botulinum toxin potentiates cancer radiotherapy and chemotherapy
Ansiaux, Réginald × Baudelet, Christine Cron, Greg O Segers, Jérôme Dessy, Chantal Martinive, Philippe De Wever, Julie Verrax, Julien Wauthier, Valérie Beghein, Nelson Grégoire, Vincent Buc Calderon, Pedro Feron, Olivier Gallez, Bernard #
Association for Cancer Research
Clinical Cancer Research vol:12 issue:4 pages:1276-1283
Structural and functional abnormalities in the tumor vascular network are considered factors of resistance of solid tumors to cytotoxic treatments. To increase the efficacy of anticancer treatments, efforts must be made to find new strategies for transiently opening the tumor vascular bed to alleviate tumor hypoxia (source of resistance to radiotherapy) and improve the delivery of chemotherapeutic agents. We hypothesized that Botulinum neurotoxin type A (BoNT-A) could interfere with neurotransmitter release at the perivascular sympathetic varicosities, leading to inhibition of the neurogenic contractions of tumor vessels and therefore improving tumor perfusion and oxygenation.